Vishal Navani

646 total citations · 1 hit paper
38 papers, 338 citations indexed

About

Vishal Navani is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Vishal Navani has authored 38 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 11 papers in Cancer Research. Recurrent topics in Vishal Navani's work include Cancer Immunotherapy and Biomarkers (18 papers), Renal cell carcinoma treatment (12 papers) and Lung Cancer Treatments and Mutations (12 papers). Vishal Navani is often cited by papers focused on Cancer Immunotherapy and Biomarkers (18 papers), Renal cell carcinoma treatment (12 papers) and Lung Cancer Treatments and Mutations (12 papers). Vishal Navani collaborates with scholars based in Canada, United States and United Kingdom. Vishal Navani's co-authors include Daniel Y.C. Heng, Igor Stukalin, Daniel E. Meyers, Aliyah Pabani, Winson Y. Cheung, Don Morris, Michelle L. Dean, Daniel Yick Chin Heng, Randeep Sangha and Craig Gedye and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Annals of Oncology.

In The Last Decade

Vishal Navani

34 papers receiving 337 citations

Hit Papers

Immune-Related Adverse Events and Survival Among Patients... 2024 2026 2025 2024 20 40 60
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
    2024 60 citations Sarah Cook, Daniel E. Meyers et al. JAMA Network Open profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vishal Navani Canada 11 205 172 87 49 42 38 338
Valeria Stati Italy 11 182 0.9× 99 0.6× 61 0.7× 27 0.6× 27 0.6× 25 319
Mitchell S. von Itzstein United States 11 222 1.1× 101 0.6× 42 0.5× 28 0.6× 60 1.4× 32 344
Kriti Mittal United States 9 137 0.7× 136 0.8× 159 1.8× 106 2.2× 32 0.8× 28 360
Melina E. Marmarelis United States 14 359 1.8× 312 1.8× 114 1.3× 98 2.0× 57 1.4× 61 590
Angélique Vienot France 12 232 1.1× 112 0.7× 57 0.7× 67 1.4× 58 1.4× 50 377
Nicholas Salgia United States 9 199 1.0× 166 1.0× 178 2.0× 76 1.6× 33 0.8× 35 362
Mingjia Li United States 10 217 1.1× 102 0.6× 61 0.7× 27 0.6× 53 1.3× 30 326
Andrew Loh United Kingdom 6 188 0.9× 119 0.7× 43 0.5× 50 1.0× 30 0.7× 6 410
Shyam Aggarwal India 9 156 0.8× 60 0.3× 71 0.8× 49 1.0× 54 1.3× 22 289
Lewis Au United Kingdom 11 267 1.3× 81 0.5× 88 1.0× 52 1.1× 86 2.0× 30 396

Countries citing papers authored by Vishal Navani

Since Specialization
Citations

This map shows the geographic impact of Vishal Navani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vishal Navani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vishal Navani more than expected).

Fields of papers citing papers by Vishal Navani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vishal Navani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vishal Navani. The network helps show where Vishal Navani may publish in the future.

Co-authorship network of co-authors of Vishal Navani

This figure shows the co-authorship network connecting the top 25 collaborators of Vishal Navani. A scholar is included among the top collaborators of Vishal Navani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vishal Navani. Vishal Navani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Phillips, William J., Ashley Jackson, Biniam Kidane, et al.. (2025). Immunotherapy for Early-Stage Non–Small Cell Lung Cancer: A Practical Guide of Current Controversies. Clinical Lung Cancer. 26(3). 179–190. 2 indexed citations
2.
3.
Cook, Sarah, Daniel E. Meyers, Igor Stukalin, et al.. (2024). Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors. JAMA Network Open. 7(1). e2352302–e2352302. 60 indexed citations breakdown →
4.
5.
6.
Stewart, David J., Sandeep Sehdev, Vishal Navani, et al.. (2024). New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices. Current Oncology. 31(5). 2453–2480. 5 indexed citations
7.
Mittal, Abhenil, Sara Moore, Vishal Navani, et al.. (2024). What Is Ailing Oncology Clinical Trials? Can We Fix Them?. Current Oncology. 31(7). 3738–3751. 3 indexed citations
8.
9.
Navani, Vishal, Daniel E. Meyers, Yibing Ruan, et al.. (2023). Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade. Clinical Lung Cancer. 24(3). e152–e159. 2 indexed citations
10.
Stukalin, Igor, Vishal Navani, Yibing Ruan, et al.. (2023). Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors. The Oncologist. 28(9). 812–822. 6 indexed citations
11.
Pabani, Aliyah, et al.. (2023). Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC. JTO Clinical and Research Reports. 4(3). 100460–100460. 7 indexed citations
12.
Stukalin, Igor, Daniel E. Meyers, Daniel Y.C. Heng, et al.. (2023). Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma. JAMA Network Open. 6(6). e2319607–e2319607. 6 indexed citations
13.
Meyers, Daniel E., Igor Stukalin, Vishal Navani, et al.. (2023). Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors. JTO Clinical and Research Reports. 4(4). 100482–100482. 14 indexed citations
14.
Navani, Vishal, T.B. Powles, Luís Meza, et al.. (2023). 1893P Immune-related adverse events from contemporary first-line combination therapies in metastatic renal cell carcinoma: Results from the IMDC. Annals of Oncology. 34. S1018–S1019. 1 indexed citations
15.
Navani, Vishal, J. Connor Wells, Devon J. Boyne, et al.. (2022). CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Clinical Genitourinary Cancer. 21(1). 106.e1–106.e8. 12 indexed citations
16.
Navani, Vishal, Moira C. Graves, Hiren Mandaliya, et al.. (2022). Melanoma: An immunotherapy journey from bench to bedside. Cancer treatment and research. 183. 49–89. 2 indexed citations
17.
Navani, Vishal, James Lynam, Steven G. Smith, Christine J. O’Neill, & Christopher W. Rowe. (2021). Castration failure in prostate carcinoma due to a functioning adrenocortical carcinoma. Endocrinology Diabetes and Metabolism Case Reports. 2021. 1 indexed citations
18.
Navani, Vishal, et al.. (2021). Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers. Pharmacology Research & Perspectives. 9(4). e00808–e00808. 7 indexed citations
19.
Navani, Vishal, Moira C. Graves, Nikola A. Bowden, & André van der Westhuizen. (2020). Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. British Journal of Clinical Pharmacology. 86(9). 1736–1752. 13 indexed citations
20.
Islam, Jasmin, Elizabeth Cheek, Vishal Navani, et al.. (2013). Influence of cohorting patients with Clostridium difficile infection on risk of symptomatic recurrence. Journal of Hospital Infection. 85(1). 17–21. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Valeria Stati Breakdown of academic impact, for papers by Mitchell S. von Itzstein Breakdown of academic impact, for papers by Kriti Mittal Breakdown of academic impact, for papers by Melina E. Marmarelis Breakdown of academic impact, for papers by Angélique Vienot Breakdown of academic impact, for papers by Nicholas Salgia Breakdown of academic impact, for papers by Mingjia Li Breakdown of academic impact, for papers by Andrew Loh Breakdown of academic impact, for papers by Shyam Aggarwal Breakdown of academic impact, for papers by Lewis Au
Rankless by CCL
2026